These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 34398669)

  • 1. Model-Based Approach for Optimizing Ceftobiprole Dosage in Pediatric Patients.
    Rubino CM; Cammarata AP; Smits A; Schröpf S; Polak M; Litherland K; Hamed K
    Antimicrob Agents Chemother; 2021 Oct; 65(11):e0120621. PubMed ID: 34398669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and Safety of Ceftobiprole in Pediatric Patients.
    Rubino CM; Polak M; Schröpf S; Münch HG; Smits A; Cossey V; Tomasik T; Kwinta P; Snariene R; Liubsys A; Gardovska D; Hornik CD; Bosheva M; Ruehle C; Litherland K; Hamed K
    Pediatr Infect Dis J; 2021 Nov; 40(11):997-1003. PubMed ID: 34533489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and Dosing of Ceftobiprole Medocaril for the Treatment of Hospital- and Community-Acquired Pneumonia in Different Patient Populations.
    Torres A; Mouton JW; Pea F
    Clin Pharmacokinet; 2016 Dec; 55(12):1507-1520. PubMed ID: 27272266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and pharmacodynamics of ceftobiprole, an anti-MRSA cephalosporin with broad-spectrum activity.
    Murthy B; Schmitt-Hoffmann A
    Clin Pharmacokinet; 2008; 47(1):21-33. PubMed ID: 18076216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects.
    Lodise TP; Pypstra R; Kahn JB; Murthy BP; Kimko HC; Bush K; Noel GJ; Drusano GL
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2378-87. PubMed ID: 17387149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase 3, Randomized, Investigator-blinded Trial Comparing Ceftobiprole With a Standard-of-care Cephalosporin, With or Without Vancomycin, for the Treatment of Pneumonia in Pediatric Patients.
    Bosheva M; Gujabidze R; Károly É; Nemeth A; Saulay M; Smart JI; Hamed KA
    Pediatr Infect Dis J; 2021 Jun; 40(6):e222-e229. PubMed ID: 33480665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo pharmacodynamics of ceftobiprole against multiple bacterial pathogens in murine thigh and lung infection models.
    Craig WA; Andes DR
    Antimicrob Agents Chemother; 2008 Oct; 52(10):3492-6. PubMed ID: 18676887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics, pharmacodynamics, and safety of single- and multiple-dose intravenous ceftobiprole in healthy Chinese participants.
    Li WZ; Wu HL; Chen YC; Guo BN; Liu XF; Wang Y; Wu JF; Zhang J
    Ann Transl Med; 2021 Jun; 9(11):936. PubMed ID: 34350251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin.
    Zhanel GG; Lam A; Schweizer F; Thomson K; Walkty A; Rubinstein E; Gin AS; Hoban DJ; Noreddin AM; Karlowsky JA
    Am J Clin Dermatol; 2008; 9(4):245-54. PubMed ID: 18572975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamic profiling of ceftobiprole for treatment of complicated skin and skin structure infections.
    Kimko H; Xu X; Nandy P; Samtani MN; Strauss RS; Bagchi P; Noel GJ
    Antimicrob Agents Chemother; 2009 Aug; 53(8):3371-4. PubMed ID: 19528285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ceftobiprole for the treatment of pneumonia.
    Cillóniz C; Dominedò C; Garcia-Vidal C; Torres A
    Rev Esp Quimioter; 2019 Sep; 32 Suppl 3(Suppl 3):17-23. PubMed ID: 31364337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and Target Attainment of Ceftobiprole in Asian and Non-Asian Subjects.
    Muller AE; Punt N; Engelhardt M; Schmitt-Hoffmann AH; Mouton JW
    Clin Pharmacol Drug Dev; 2018 Sep; 7(7):781-787. PubMed ID: 29768717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ceftobiprole: a novel cephalosporin with activity against Gram-positive and Gram-negative pathogens, including methicillin-resistant Staphylococcus aureus (MRSA).
    Barbour A; Schmidt S; Rand KH; Derendorf H
    Int J Antimicrob Agents; 2009 Jul; 34(1):1-7. PubMed ID: 19261449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ceftobiprole medocaril: a review of its use in patients with hospital- or community-acquired pneumonia.
    Syed YY
    Drugs; 2014 Sep; 74(13):1523-42. PubMed ID: 25117196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population Pharmacokinetic Assessment and Pharmacodynamic Implications of Pediatric Cefepime Dosing for Susceptible-Dose-Dependent Organisms.
    Shoji K; Bradley JS; Reed MD; van den Anker JN; Domonoske C; Capparelli EV
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2150-6. PubMed ID: 26810655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ceftobiprole medocaril for the treatment of community-acquired pneumonia.
    Falcó V; Burgos J; Almirante B
    Expert Opin Pharmacother; 2018 Sep; 19(13):1503-1509. PubMed ID: 30198789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population PK Modeling and Target Attainment Simulations to Support Dosing of Ceftaroline Fosamil in Pediatric Patients With Acute Bacterial Skin and Skin Structure Infections and Community-Acquired Bacterial Pneumonia.
    Riccobene TA; Khariton T; Knebel W; Das S; Li J; Jandourek A; Carrothers TJ; Bradley JS
    J Clin Pharmacol; 2017 Mar; 57(3):345-355. PubMed ID: 27510635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic and pharmacodynamics evaluation of ceftobiprole medocaril for the treatment of hospital-acquired pneumonia.
    Lagacé-Wiens PR; Rubinstein E
    Expert Opin Drug Metab Toxicol; 2013 Jun; 9(6):789-99. PubMed ID: 23590397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ceftobiprole medocaril in the treatment of hospital-acquired pneumonia.
    Scheeren TW
    Future Microbiol; 2015; 10(12):1913-28. PubMed ID: 26573022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ceftobiprole quantification in human serum by HPLC-UV to implement routine TDM in clinical practice.
    Boccardi D; Marini V; Baiardi G; Cameran Caviglia M; Sacco F; Piras F; Del Puente F; Boni S; Pontali E; Mattioli F
    Clin Chim Acta; 2024 Jul; 561():119806. PubMed ID: 38852792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.